E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
chronic obstructive pulmonary disease (COPD) |
|
E.1.1.1 | Medical condition in easily understood language |
chronic obstructive pulmonary disease (COPD) |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Respiratory Tract Diseases [C08] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 19.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10010952 |
E.1.2 | Term | COPD |
E.1.2 | System Organ Class | 100000004855 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine the effect of once-daily QVA149 (110/50 µg o.d.) compared with placebo on left ventricular enddiastolic volume as measured by MRI after 2 weeks of treatment in hyperinflated COPD patients.
|
|
E.2.2 | Secondary objectives of the trial |
• To evaluate the effects of QVA149 compared to placebo on lung function parameters after 14 days of treatment, as measured by:
o Forced spirometry (75 min post-dose)
- FEV1 and FVC
o Bodyplethysmography (60 min post-dose):
- inspiratory capacity (IC)
- total lung capacity (TLC)
- residual volume (RVol)
- specific airway resistance (sRaw)
- functional residual capacity (FRC)
To evaluate the effects of QVA149 compared to placebo on cardiac parameters, as measured by MRI after 14 days of treatment:
o right and left ventricular ejection fraction
o right and left ventricular endsystolic volumes
o right ventricular enddiastolic volume
o cardiac output
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Written informed consent must be obtained before any assessment is performed.
2. Male or female subjects, aged ≥ 40 years, giving written Informed Consent and who are willing and capable to comply with all study procedures.
3. Patients with stable COPD according to the current GOLD guidelines (GOLD 2014).
4. Patients with airflow limitation indicated by a post-bronchodilator FEV1 <80% of the predicted normal value and a post-bronchodilator FEV1/FC<0.7 at Visit 3. Post-bronchodilator refers to within 10-15 min after inhalation of 400 µg (4x100 µg) of salbutamol.
5. Current or ex-smokers who have a smoking history of at least 10 pack years. (Ten pack-years are defined as 20 cigarettes a day for 10 years, or 10 cigarettes a day for 20 years etc.)
6. Hyperinflated patients with RVol>135% predicted as measured at Visit 3, before intake of salbutamol.
|
|
E.4 | Principal exclusion criteria |
1. Pat. with conditions contraindicated for treatment with, or having a history of reactions/hypersensitivity to any of the following inhaled drugs, drugs of a similar class or any component thereof
• anticholinergics
• long and short acting beta-2 agonists
• sympathomimetic amines
• lactose or any of the other excipients
2. Pat. with a history of long QT syndrome or whose QTcF (Fredericia method) measured at Visit 3 is prolonged (>450 ms for males and >470 ms for females). These patients should not be re-screened.
3. Pat. who have a clinically significant abnormality on the ECG at Visit 3, who in the judgment of the investigator would be at potential risk if enrolled into the study. These patients should not be re-screened.
4. Pat. who have clinically significant cardiovascular abnormalities, which could interfere with the assessment of the study treatment
5. Pat. with a known history or current atrial fibrillation to be confirmed by ECG at Visit 3.
6. Pat. with pacemaker or bypass.
7. Pat. with a mean sitting systolic blood pressure >160 mmHg and/or mean sitting diastolic blood pressure >90 mmHg at Visit 3. These pats. will be permitted to be rescreened after having achieved controlled disease status following initiation or intensification of antihypertensive therapy. Re-screening can start at Visit 2, 4 weeks after change of antihypertensive medication.
8. Past or present disease, which as judged by the investigator, may affect the outcome of this study. These diseases include, but are not limited to history of hepatic disease, renal disease, hematological disease, neurological and psychiatric disease, endocrine disease or pulmonary disease other than COPD (including but not confined to tuberculosis, bronchiectasis, cystic fibrosis, pulmonary hypertension, sarcoidosis, interstitial lung disease or lung fibrosis).
9. History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.
10. Pat. with narrow-angle glaucoma, symptomatic benign prostatic hyperplasia or bladder-neck obstruction or severe renal impairment (GFR<30 mL/min/1.73 m2) including those with end-stage renal disease requiring dialysis or urinary retention. Benign Prostatic Hyperplasia (BPH) patients who are stable on treatment can be considered.
11. Pat. with Type I or uncontrolled Type II diabetes.
12. Pat. with active/ clinical history of asthma.
13. Pat. unable to undergo MRI scans, including claustrophobia or presence of any metal objects within the patient, preventing from MRI scan. A separate MRI patient informed consent form including MRI safety will be signed by the patient before each MRI exam.
14. History of lower respiratory tract infection within four weeks prior to Visit 2 and between Visit 2 and Visit 4. These patients will not be eligible, but will be permitted to be re-screened 4 weeks after the resolution of the respiratory tract infection and can re-start at Visit 2.
15. History of one COPD exacerbation that required treatment with antibiotics, systemic steroids or hospitalization within 3 months prior to Visit 2.
16. More than one COPD exacerbation that required treatment with antibiotics, systemic steroids or hospitalization within 6 months prior Visit 2.
17. Pat. who develop a COPD exacerbation between Visit 2 and Visit 4 will not be eligible but will be permitted to be re-screened after a minimum of 3 months after the resolution of the COPD exacerbation and can re-start at Visit 2.
18. Pat. requiring long term oxygen therapy on a daily basis for chronic hypoxemia.
19. Pat. with active pulmonary tuberculosis, unless confirmed by imaging in the last year to be no longer active.
20. Pat. with pulmonary lobectomy or lung volume reduction surgery or lung transplantation.
21. Pat. with a diagnosis of alpha 1 anti-trypsin deficiency.
22. Pat. with a body mass index of more than 40 kg/m2.
23. Pat. participating in or planning to participate in the active phase of a supervised pulmonary rehabilitation program during the study
24. Pat. who are, in the opinion of the investigator known to be unreliable or non-compliant.
25. Relevant history of drug or alcohol abuse as judged by the investigator.
26. Suspected inability to understand the protocol requirements, instructions and study-related restrictions, the nature, scope, and possible consequences of the study
27. Use of other investigational drug at the time of enrollment, or within 30 days or 5 half-lives of Visit 1, whichever is longer.
28. Pat. receiving any medication in the classes listed in Table 5-1 and Table 5-2.
29. Pat. receiving medication in the classes listed in Table 5-3 should be excluded unless the medication has been stable for the specified period and the stated conditions have been met.
30. Women who are pregnant or breast feeding
31. Women of child-bearing potential |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy variable is the left ventricular enddiastolic volume assessed by MRI after 2 weeks of treatment. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
All secondary endpoints (lung function- and other cardiac function parameters) will be analyzed analogous to the primary endpoint. Exploratory endpoints and Qol-measurements will be analyzed descriptively. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |